Loading organizations...
§ Private Profile · Los Gatos, CA, USA
Medical device company developing mechanical thrombectomy systems to treat venous thromboembolism, deep vein thrombosis, and pulmonary embolism.
Based in Campbell, California, Akura Medical is a medical device company that develops mechanical thrombectomy systems and integrated imaging software to treat venous thromboembolism. The company provides hospitals and vascular surgeons with its proprietary Katana Thrombectomy System, which is designed to remove blood clots associated with deep vein thrombosis and pulmonary embolism. Operating with approximately 10 employees, the enterprise recently closed a $53 million Series C financing round following a $35 million Series B. Akura Medical is backed by institutional investors including Cormorant Asset Management, The Capital Partnership, AMED Ventures, and Themeda Trust. The firm recently secured FDA clearance and initiated its United States pivotal clinical trial for pulmonary embolism treatments. The company was founded in 2019 by Amr Salahieh and Aadel Al-Jadda as a portfolio company of the medical innovation incubator Shifamed.
Akura Medical has raised $113.0M across 3 funding rounds.
Akura Medical has raised $113.0M in total across 3 funding rounds.
Akura Medical has raised $113.0M across 3 funding rounds. Most recently, it raised $53.0M Series C in December 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 1, 2025 | $53M Series C | Qatar Investment Authority | — | Announced |
| Oct 3, 2023 | $35M Series B | Cormorant Asset Management, Gautam Kainth | AMED Ventures, Lilly Asia Ventures, PA MedTech, Unorthodox Ventures | Announced |
| Jan 10, 2022 | $25M Series A | Bihua Chen | PA MedTech, AMR Salahieh, The Capital Partnership | Announced |
Akura Medical has raised $113.0M in total across 3 funding rounds.
Akura Medical's investors include Qatar Investment Authority, Cormorant Asset Management, Gautam Kainth, AMED Ventures, Lilly Asia Ventures, PA MedTech, Unorthodox Ventures, Bihua Chen, Amr Salahieh, The Capital Partnership.